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Abstract
Background: Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine malignancy with limited
treatment options. Several lines of evidence support the programmed death-1/programmed death-ligand 1 (PD-1/
PD-L1) axis as a likely contributor to immune evasion in MCC.
Case presentation: We report a case of a patient with metastatic MCC with a significant and durable response to
nivolumab, a humanized IgG4 monoclonal anti-PD-1 antibody.
Conclusion: Immunotherapy with PD-1/PD-L1 inhibitors has become a rational and promising treatment option for
MCC in the advanced or metastatic disease. Clinical trials are currently in progress to further evaluate these novel
therapeutic agents.
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Background
Merkel cell carcinoma (MCC) is a rare and aggressive
cutaneous neuroendocrine malignancy with an annual
incidence rate of 0.6 per 100,000 persons [1]. MCC is
frequently diagnosed in the elderly in areas of sun-
exposed skin and remains a challenging disease to treat.
It has a high frequency of local recurrence (30 %) com-
pared to melanoma (3.8 %), and more than 40 % of
patients eventually develop distant metastatic disease
[2, 3]. Early stage disease is typically managed by
surgical excision with or without radiotherapy [4].
Adjuvant radiotherapy may improve locoregional con-
trol for some tumors, but it is unclear if it impacts
survival [5, 6]. Patients with unresectable locally
advanced or metastatic disease are most often treated
with chemotherapy [7]. While there are currently no
Food and Drug Administration (FDA) approved ther-
apies for advanced MCC, platinum in combination
with etoposide has been the standard for advanced
stage MCC based on data from small cell lung carcin-
oma. Cyclophosphamide, doxorubicin and vincristine
have also been tried with variable response rates [8].
Unfortunately, responses to chemotherapy are not
durable and have not clearly demonstrated a survival
advantage [9]. New approaches for the disease are
needed.
Case presentation
We report a case of a man in his 80s who initially noted
a lesion on his right back thought to be an infected cyst
in 2014. Evaluation noted right axillary adenopathy,
which prompted a biopsy of the mass and of the cyst-
like lesion. Pathology demonstrated morphologic and
immunohistochemical (strongly cytokeratin-20, neuron
specific enolase and CD56 positive and thyroid tran-
scription factor-1 negative) findings in both lesions con-
sistent with MCC. Polymerase chain reaction performed
on deoxyribonucleic acid extracted from formalin-fixed,
paraffin-embedded tumor tissue alongside appropriate
controls using a previously described protocol demon-
strated that the tumor lacked detectable Merkel cell
polyomavirus (MCPyV) large T antigen and small T anti-
gen [10, 11]. Staging fluorodeoxyglucose-positron emis-
sion tomography/computed tomography (FDG-PET/CT)
revealed lesions in right upper lung, right upper back,
right axilla and right adrenal gland consistent with meta-
static disease (Fig. 1a, b and c). Subsequent biopsy of the
right lung confirmed metastatic MCC. Following exten-
sive discussions regarding the implications and options,
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he refused chemotherapy. At that time, no clinical trial
was available to him, but programmed death-1 (PD-1)
inhibitor therapy was being tested on trial (Clinical-
Trials.gov. NCT02267603). Nivolumab, a humanized
IgG4 monoclonal anti-PD-1 antibody, was obtained from
Bristol-Myers-Squibb outside of a clinical trial, and he
was subsequently treated with nivolumab 3 mg/kg intra-
venously every 2 weeks for six cycles in 2015. Following
two cycles, he had an excellent partial response on phys-
ical exam with decreased adenopathy. After five cycles,
he achieved a marked partial metabolic response by
FDG-PET/CT (Fig. 1d, e and f). He continued on ther-
apy, but after cycle six, treatment was complicated by
pneumonia and autoimmune hepatitis. He improved on
intravenous steroids at an outside hospital and was
discharged on prednisone 1 mg/kg per day. He com-
pletely recovered with a slow steroid taper, and no
further treatment with nivolumab was given. He contin-
ued on surveillance alone for 8 months, and his disease
remained well controlled with no recurrence on physical
exam and at least an excellent partial response in his
distant metastasis with no new sites of disease.
Conclusions
As our understanding of the oncogenic pathways of
MCC evolves, immunotherapy has become a rational
and promising treatment option in the advanced or
metastatic setting. In 2008, Feng et al. identified a clon-
ally integrated polyomavirus (MCPyV) in the majority
(85 %) of human MCCs [12]. Although the oncogenic
potential of MCPyV is still being elucidated, the
increased risk of MCC in the setting of immunosuppres-
sion supports its viral-mediated origin. Circulating anti-
bodies to MCPyV T antigen and MCPyV-specific CD8
and CD4 T-cells have been identified in patients with
MCC, but appear unable to eradicate MCPyV positive
cells despite immune activation. Several lines of evidence
support the expression of programmed death-1/pro-
grammed death-ligand 1 (PD-1/PD-L1) as a likely con-
tributor to immune evasion in MCC [13, 14]. Lipson et al.
analyzed 67 specimens from 49 patients for PD-L1
expression by immunohistochemistry and demon-
strated tumor cells and immune infiltrates expressed
PD-L1 (49 % and 55 %, respectively) with 97 % of
PD-L1-expressing MCC cells geographically associated
with immune infiltrates [15]. Afanasiev et al. reported
a higher expression of MCPyV specific circulating T-cells
with PD-1 expression compared to control Epstein-Barr
virus and cytomegalovirus specific T-cells (p < 0.01) [16].
They also found that blocking PD-1 led to augmentation
of MCPyV specific T-cell function [16]. Additionally,
tumors with high PD-L1 expression were more likely to
have CD8 lymphocyte infiltration than tumors with lower
PD-L1 expression [16]. Other investigators demonstrated
that 50 % of non-activated T cells expressed PD-1, which
is thought to be a marker of T cell exhaustion [17]. Taken
together, these data strongly support the PD-1/PD-L1 in-
hibitory axis as an immune evasion strategy for MCC, and
Fig. 1 Baseline and repeat FDG-PET/CT scan illustrating areas of FDG uptake. Legend: a, b and c Baseline FDG-PET/CT scan revealed hypermetabolic
activity consistent with metastatic disease. d, e and f Repeat FDG-PET/CT scan following cycle 5 of nivolumab demonstrated significant decrease in size
and FDG uptake of all sites of disease
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targeting this negative signal of T-cell activation could be
an important treatment approach against MCC.
Immunohistochemistry performed retrospectively on
the tumor excised from the patient’s back demonstrated
variable expression of PD-1 in tumor-associated lympho-
cytes (Fig. 2a and b). PD-L1 testing demonstrated patchy
staining of tumor-associated inflammatory cells, pre-
dominantly histiocytes (Fig. 2c and d). There was no
significant expression of PD-L1 in MCC tumor cells in
comparison to positive controls. This finding is consist-
ent with other cancers treated with PD-1 inhibitors in
that PD-L1 expression may not predict the benefit from
these agents [18]. Mutational load was not examined in
this case. However, based on recent genomic findings in
MCPyV-negative tumors, we would predict this MCPyV-
negative case to display a high mutational burden with
associated neoantigens that may result in susceptibility to
immunotherapy [11, 19].
Preliminary results of two phase II trials provide
additional evidence of PD-1 and PD-L1 inhibition as a
valid and promising therapeutic approach [20, 21].
Nghiem and colleagues demonstrated that pembrolizu-
mab (a PD-1 inhibitor) has a 56 % overall response rate
in chemotherapy naïve patients with response durations
ranging from 2.2 months to at least 9.7 months [20].
Avelumab (a PD-L1 inhibitor) was tested in patients
with chemotherapy-refractory MCC and was shown to
have a response rate of 31.7 %, with 82 % of respondents
having ongoing responses at a median follow-up of
10.4 months [21]. This case highlights the potential
therapeutic benefit of nivolumab, including durability of
response with immunotherapy for MCC. A clinical trial
evaluating nivolumab as a treatment option for virus-
associated cancers, including MCC, is currently being
conducted (ClinicalTrials.gov. NCT02155647).
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Fig. 2 PD-1 and PD-L1 expression in Merkel cell carcinoma primary tumor from the right upper scapula. Legend: a, b: PD-1 shows patchy expres-
sion in tumor-associated lymphocytes. c, d: There is no significant PD-L1 expression in tumor cells. Background inflammatory cells express patchy
PD-L1, predominantly in larger cells consistent with histiocytes (yellow arrowheads). Magnification 40x (a, c) or 400x (b, d)
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